

Monday, 29 September 2025

ACL and Australian Information Commissioner reach agreement on Privacy Act proceeding

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) advises that it has reached an agreement with the Australian Information Commissioner (AIC) to resolve the civil penalty proceeding commenced in the Federal Court of Australia in November 2023 relating to a cyberattack on Medlab Pathology that occurred in February 2022 (**Medlab Cyberattack**). The Medlab Cyberattack occurred approximately nine weeks following ACL's acquisition of the Medlab business. ACL's data and IT systems were not impacted by the Medlab Cyberattack.

Under the agreement, ACL and the AIC have:

- filed a Statement of Agreed Facts and Admissions and joint submissions with the Federal Court; and
- proposed to the Federal Court that ACL pay a penalty of \$5.8 million in relation to contraventions of the Privacy Act 1988, and a contribution of \$400,000 towards the AIC's legal costs.

The agreement remains subject to Federal Court approval and the Court today reserved its judgment.

There is no expected material impact on the ongoing operations or financial position of ACL beyond the agreed settlement amount.

Following ACL's acquisition of the Medlab business, Medlab's IT systems were integrated into ACL's IT systems and are subject to ACL's robust cybersecurity framework and protections.

ACL would like to again apologise to the Medlab customers and employees that were impacted as a result of this Cyberattack. While the Medlab Cyberattack was isolated to the newly acquired Medlab business, we remain steadfast in our commitment to the protection of patient data, data governance and continuously improving our cybersecurity systems and controls.

This resolution allows ACL to move forward with certainty and focus on our strategic objectives and continued delivery of high-quality pathology service to our patients and value to shareholders.

– ENDS –

This announcement was authorised for release to ASX by Eleanor Padman, Company Secretary of ACL. For further information regarding this announcement, please contact:

Media

Sue Cato

Email: cato@catoandclive.com

Phone: +61 (0)419282319

Company Secretary

Eleanor Padman

Company Secretary

Email: epadman@padmanadvisory.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.